Our Pipeline

Our platform technology enables the development of broad antimicrobial treatments that has the potential to significantly improve the lives of patients with acute and chronic disease.

Our strategy is to identify targets where our poly-therapeutic can potentially impact patient populations at significant risk of contracting or developing a multi-drug resistant pathogen.

Our current primary asset is in late-stage, pre-clinical testing to treat pulmonary bacterial and fungal disease.